Colagiuri () Risk of bias Subgroup of AusDiab Subgroup not described. Larger 6.1 mmol/L≥ FPG ROC Level III-2 ≥5.3% ≥5.3% Australia unclear; study, population study recruited from FPG ≥7.0 analysis for Subgroup study of stratified random sample. <7.0 mmol/L; people with analysis of study, diabetes prevalence. HbA1c participants in 7.8 mmol/L≥ 2hPG results given Subgroup determined ≥5.3% 2hPG ≥11.0 on a subgroup by presence of at study of <11.1 mmol/L with at least least one risk factor, diabetes one risk but subgroup not prevalence. factor. described at all. High applicability as Australian setting. Different to current Cosson () Low risk of Patients referred to Excluded patients with known Not Not 6.0 mmol/L> FPG Sensitivity Level III-2 Paris, France bias. hospital clinic for diabetes. Included patients with reported reported FPG ≥7.0 and Inpatients treatment of comorbidities but no acute disease. <7.0 mmol/L; specificity Cohort also without known Applicable to overweight or obesity, reported in diabetes Australian 7.8 mmol/L≥ 2hPG free of any acute meta-analysis referred for setting. 2hPG ≥11.1 disease but likely to (Cosson ) OGT testing as <11.1 mmol/L Appropriate be at high risk. part of battery of cut-offs. N=1,287, 82% tests. female, mean age 39 ± 14 years, range 16–76 years. Gomyo () Level III-2 Low risk of Population not well Exclusions not reported. Not Not IGT: FPG ROC Various bias. described; n=997. reported reported ≥126 analysis Patients To have OGT test, patients had to FPG locations, identified with Applicability have: <126 mg/dL; Japan pre-diabetes uncertain as 140 mg/dL≥ 2hPG (1) 100 mg/dL≤ FPG <126 mg/dL; after initial population not 2hPG ≥200 (2) 140 mg/dL≤ casual plasma screening for an well <200 mg/dL; glucose (CPG) <200 mg/dL (less than RCT of described; IFG:
Colagiuri () Australia Level III-2 Subgroup analysis of participants in study of diabetes prevalence. Risk of bias unclear; study, results given on a subgroup with at least one risk factor. High applicability as Australian setting. Different to current Subgroup of AusDiab study, study of diabetes prevalence. Subgroup determined by presence of at least one risk factor, but subgroup not described at all. Subgroup not described. Larger population study recruited from stratified random sample. ≥5.3% ≥5.3% 6.1 mmol/L≥ FPG <7.0 mmol/L; 7.8 mmol/L≥ 2hPG <11.1 mmol/L FPG ≥7.0 2hPG ≥11.0 ROC analysis for people with HbA1c ≥5.3% Cosson () Paris, France Cohort also reported in meta-analysis (Cosson ) Level III-2 Inpatients without known diabetes referred for OGT testing as part of battery of tests. Low risk of bias. Applicable to Australian setting. Appropriate cut-offs. Patients referred to hospital clinic for treatment of overweight or obesity, free of any acute disease but likely to be at high risk. N=1,287, 82% female, mean age 39 ± 14 years, range 16–76 years. Excluded patients with known diabetes. Included patients with comorbidities but no acute disease. Not reported Not reported 6.0 mmol/L> FPG <7.0 mmol/L; 7.8 mmol/L≥ 2hPG <11.1 mmol/L FPG ≥7.0 2hPG ≥11.1 Sensitivity and specificity Gomyo () Various locations, Japan Level III-2 Patients identified with pre-diabetes after initial screening for an RCT of Low risk of bias. Applicability uncertain as population not well described; Population not well described; n=997. Exclusions not reported. To have OGT test, patients had to have: (1) 100 mg/dL≤ FPG <126 mg/dL; (2) 140 mg/dL≤ casual plasma glucose (CPG) <200 mg/dL (less than Not reported Not reported IGT: FPG <126 mg/dL; 140 mg/dL≥ 2hPG <200 mg/dL; IFG: FPG ≥126 2hPG ≥200 ROC analysis
1267-FinalContractedAssessmentReport-accessible.DOCX